food and drug administration fda

FDA Approves 1st Non-Opioid Pain Medicine in 20 Years

What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades

This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.

The Washington Post · 1h

FDA approves new, non-opioid painkiller Journavx

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

ABC · 1h

FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain.

FDA, recall

MLive · 56m

This chocolate recall has been upgraded to FDA’s highest risk level

STATEN ISLAND, N.Y. — A December 2024 chocolate recall has been upgraded to highest risk level by the U.S. Food and Drug Administration (FDA), which says consuming the product could “cause serious adverse health consequences or death.”

New York Daily News · 3h

Lay’s recall increased to highest level, could cause ‘death’: FDA

The oversight could result in “death,” at least for those with a milk allergy or sensitivity, says the FDA. FDA initiated the recall on Dec. 13 and announced three days later that it was recalling the chips due to a potential or undeclared allergen. At present, no allergic reactions have been reported.

Newsweek on MSN · 9h

Salad Recall Update as FDA Sets Highest Risk Level

The U.S. Food and Drug Administration ( FDA) has set its highest risk level—a Class I recall—over potential salmonella contamination in salad products.

FDA, migraine and Symbravo

Reuters · 5h

US FDA approves Axsome Therapeutics' migraine drug

The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday.

Business Insider · 4h

Axsome Therapeutics announces FDA approval of Symbravo

Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in

Investing.com on MSN · 3h

FDA approves new migraine treatment SYMBRAVO

NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO®,

WISH-TV on MSN2h

FDA redefines ‘healthy’ food labels to help consumers make informed choices

The FDA is overhauling food labels to redefine "'healthy," focusing on redefining terms and introducing new front-of-package ...

US FDA identifies cybersecurity risks in certain patient monitors

The U.S. Food and Drug Administration (FDA) said on Thursday it had identified three cybersecurity risks associated with certain patient monitors from Contec and Epsimed and urged healthcare ...

4don MSN

Food and Drug Administration wants to put nutrition labels front and center on food products

The U.S. Food and Drug Administration wants to put nutrition information front and center on food products to give consumers ...

4hOpinion

Do food warning labels actually work? Answering your questions.

Readers had a lot to say about my latest column on the Food and Drug Administration’s proposed front-of-package labels. Most ...

FDA approves Ozempic to help reduce risk of worsening chronic kidney disease

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

PBS5d

The FDA banned Red 3 food coloring. A scientist explains the dye’s history and health risks

Over 35 years after the first study linking the artificial food dye Red 3 to thyroid cancer in rats was published, the U.S.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA Approves 1st Non-Opioid Pain Medicine in 20 Years

FDA, recall

FDA, migraine and Symbravo

Related topics